Bronchiolitis

Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month

Retrieved on: 
Monday, April 15, 2024
Education, Sarcoidosis, University, Inflammation, Pharmacy, Hospital, Blood, Respiratory syncytial virus, Death, Partnership, Research, Vaccine, Medicine, Bronchiolitis, Disease, Conditional sentence, Nervous system, University of Alabama, Patient, Immunodeficiency, UAB, Caregiver, Lung, Diagnosis, Infection, RSV, FSR, Pharmaceutical industry

CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation’s medically underserved populations, and Foundation for Sarcoidosis Research (FSR), the leading international sarcoidosis organization, are proud to announce its renewed partnership to raise education and awareness about sarcoidosis and the importance of spring vaccinations with all Alabama-based Walgreens stores. As part of April’s Sarcoidosis Awareness Month from now through April 30th, all Walgreens stores in Alabama will join forces with FSR in an effort to spread awareness and support those affected by this chronic disease.

Key Points: 
  • As part of April’s Sarcoidosis Awareness Month from now through April 30th, all Walgreens stores in Alabama will join forces with FSR in an effort to spread awareness and support those affected by this chronic disease.
  • During this awareness campaign, Walgreens stores across Alabama will provide informational resources about sarcoidosis to their customers.
  • Every donation will directly support FSR’s initiatives to accelerate sarcoidosis research and provide crucial support to patients and their families.
  • FSR is proud to partner with Walgreens to raise awareness of the spring respiratory vaccines, which include RSV and Pneumonia.

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Retrieved on: 
Wednesday, April 10, 2024
Phase, Inhalation, Pneumonia, Bronchiolitis, Therapy, Urinary tract infection, Incidence, Lung, Plasma, RSV, Pharmaceutical industry

SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

Key Points: 
  • SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.
  • This drug is indicated for respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children.
  • As mentioned by relevant R&D directors of Kexing Biopharm, the Phase I clinical dose-escalation and bronchoalveolar lavage studies of Kexing Biopharm's Human Interferon α1b Inhalation Solution were completed in October 2023.
  • Human Interferon α1b Inhalation Solution, another significant breakthrough in the antiviral field achieved by Kexing Biopharm, is expected to fill this market void.

R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm

Retrieved on: 
Wednesday, April 10, 2024
Phase, Inhalation, Pneumonia, Bronchiolitis, Therapy, Urinary tract infection, Incidence, Lung, Plasma, RSV, Pharmaceutical industry

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first patient and dosing.
  • This drug is indicated for respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children.
  • As mentioned by relevant R&D directors of Kexing Biopharm, the Phase I clinical dose-escalation and bronchoalveolar lavage studies of Kexing Biopharm's Human Interferon α1b Inhalation Solution were completed in October 2023.
  • Human Interferon α1b Inhalation Solution, another significant breakthrough in the antiviral field achieved by Kexing Biopharm, is expected to fill this market void.

Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections

Retrieved on: 
Thursday, March 14, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Human, Infection, Bronchiolitis, Risk, Viral load, COVID-19, Inflammation, Lung, PIV, SARS-CoV-2, RSV, IND, Antibody, Omicron, Biological engineering, Translational medicine, Vaccine, Animal, Advanced Science

Inhalon Biopharma (Inhalon), a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections, today announced the publication of preclinical data showcasing the advantages and efficacy of its “muco-trapping” technology in animal models of respiratory syncytial virus (RSV) and SARS-CoV-2 infections.

Key Points: 
  • Inhalon Biopharma (Inhalon), a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections, today announced the publication of preclinical data showcasing the advantages and efficacy of its “muco-trapping” technology in animal models of respiratory syncytial virus (RSV) and SARS-CoV-2 infections.
  • “Inhalon’s approach rethinks the use of antibodies for the treatment of acute respiratory infections by delivering antibodies directly to the site of the infection,” said John Whelan, president and chief executive officer, Inhalon Biopharma.
  • “Our studies in Advanced Science and in Bioengineering and Translational Medicine demonstrate the exceptional effectiveness of our inhaled antibody platform, which offers the potential to treat a wide array of acute respiratory infections.
  • With the support of the USAMRDC, Inhalon has begun preclinical activities and manufacturing to advance this candidate into the clinic in 2025.

SafeDose Adds Pediatric Education Resources to its Acute Care Medication Safety Software

Retrieved on: 
Tuesday, February 27, 2024
EDS, Hospital, Sepsis, BSN, Nursing, Multimedia, Shock, RN, Education, Croup, ENPC, Asthma, Anaphylaxis, Bronchiolitis, ED, Curriculum, Patient, Seizure, Premium, PALS

SOUTHBOROUGH, Mass., Feb. 27, 2024 /PRNewswire-PRWeb/ -- SafeDose®, a pioneer in the safe, simple, and standardized delivery of pediatric medication in acute care settings, has added a comprehensive set of educational tools which can be used to train nurses who care for pediatric patients in emergency settings. The Pediatric Education Resources package is included with the Premium subscription offering for the SafeDose drug administration software suite.

Key Points: 
  • SOUTHBOROUGH, Mass., Feb. 27, 2024 /PRNewswire-PRWeb/ -- SafeDose®, a pioneer in the safe, simple, and standardized delivery of pediatric medication in acute care settings, has added a comprehensive set of educational tools which can be used to train nurses who care for pediatric patients in emergency settings.
  • The Pediatric Education Resources package is included with the Premium subscription offering for the SafeDose drug administration software suite.
  • The SafeDose Pediatric Education Resources include comprehensive simulation planners, quick visual in-service sheets, and brief videos on where to find further point-of-care and educational content within the SafeDose software.
  • This bundle includes access to the asthma section within the SafeDose software, asthma Readiness Resources, and asthma Education Resources.

An RSV vaccine has been approved for people over 60. But what about young children?

Retrieved on: 
Wednesday, January 17, 2024
Bronchiolitis, Placenta, Infection, Hospital, Pneumonia, Influenza, Life, Fatigue, Cold medicine, GSK, COVID, Therapeutic Goods Administration, Infant, Vaccination, Croup, Risk, Palivizumab, Human, Disease, Child, Pregnancy, Chimpanzee, Antibody, TGA, Respiratory syncytial virus, Time, Vaccine, News, SARS-CoV-2, RSV, Nirsevimab, Immune system

The Therapeutic Goods Administration (TGA) has approved a vaccine against respiratory syncytial virus (RSV) in Australia for the first time.

Key Points: 
  • The Therapeutic Goods Administration (TGA) has approved a vaccine against respiratory syncytial virus (RSV) in Australia for the first time.
  • RSV is a contagious respiratory virus which causes an illness similar to influenza, most notably in babies and older adults.

A bit about RSV

  • There are two key groups of people we would like to protect from RSV: babies (up to about one year old) and people older than 60.
  • In babies and younger children, RSV generally causes a wheezing asthma-like illness (bronchiolitis), but can also cause pneumonia and croup.

RSV vaccines for older people

  • For older adults, there are actually several RSV vaccines in the pipeline.
  • The GSK and Pfizer RSV vaccines are similar.
  • Both vaccines have been shown to reduce illness from RSV by more than 80% in the first season after vaccination.

Protecting young children from RSV

  • To prevent other diseases, this can be overcome by giving multiple vaccine doses over time.
  • But the highest risk group for RSV are those in the first few months of life.
  • To protect this youngest age group from the virus, there are two potential strategies available instead of vaccinating the child directly.
  • Abrysvo, the Pfizer RSV vaccine, has been trialled in pregnant women.
  • In clinical trials, this vaccine has been shown to reduce illness in infants for up to six months.
  • It has been approved in pregnant women in the United States, but is not yet approved in Australia.

What now?

  • RSV, like influenza, is a major cause of respiratory illness, and the development of effective vaccines represents a major advance.
  • While the approval of the first vaccine for older people is an important step, many details are yet to be made available, including the cost and the timing of availability.


Allen Cheng receives funding from the National Health and Medical Research Council and the Australian Government. He is a member of the Australian Technical Advsory Group on Immunisation. The views expressed in this article may not reflect those of ATAGI.

RSV, flu and COVID: demystifying the triple epidemic of respiratory viruses

Retrieved on: 
Tuesday, January 16, 2024
Mortality, Bronchiolitis, Patient, Research, Infection, Pneumonia, Hospital, Incidence, Health, Wheeze, Fatigue, COVID, Vaccination, Respiratory system, Disease, Immunodeficiency, Pandemic, Aerosol, COVID-19, Virus, Population, Season, Pregnancy, Atmosphere, Immunity, Vaccine, Periodic breathing, SARS-CoV-2, RSV

Since 2022, a triple epidemic of respiratory viruses — RSV, influenza and SARS-CoV-2 — has been disrupting our daily lives. In addition, the media constantly reminds us of how this is straining emergency departments. How does the present respiratory virus season differ from seasons during the pre-COVID era? As a specialist in virus-host interaction, I would like to shed some light on the new dynamics of the respiratory virus season.The infamous SARS-CoV-2Despite limited access to screening tests, analysis of the number of hospital admissions shows that the virus is still going strong.

Key Points: 


Since 2022, a triple epidemic of respiratory viruses — RSV, influenza and SARS-CoV-2 — has been disrupting our daily lives. In addition, the media constantly reminds us of how this is straining emergency departments. How does the present respiratory virus season differ from seasons during the pre-COVID era? As a specialist in virus-host interaction, I would like to shed some light on the new dynamics of the respiratory virus season.

The infamous SARS-CoV-2

  • Despite limited access to screening tests, analysis of the number of hospital admissions shows that the virus is still going strong.
  • It has a strikingly efficient capacity to spread through aerosols, especially as we take refuge indoors to escape the cold.

Resurgence of seasonal flu

  • After a hiatus due to health measures, the influenza virus, which causes seasonal flu, has returned with the same force.
  • It is once again circulating in different variants belonging to Types (strains) A and B, although scientists believe that one Type B strain, the Yamagata lineage, has disappeared.

And what about RSV?

  • Bronchiolitis is characterized by the obstruction of the small airways, which can progress to wheezing or respiratory distress.
  • But RSV also severely affects the elderly and adults who are immunocompromised or have existing chronic conditions.
  • Admittedly, although these three viruses are attracting attention, other less publicized respiratory viruses are also circulating, demonstrating a diverse viral environment.

SARS-CoV-2 has turned everything upside down

  • The challenge is amplified by the extremely high transmission capacity of SARS-CoV-2 compared with influenza and RSV, which makes seasonal management much more complex.
  • But today, the picture has become even more complex with the continuing presence of SARS-CoV-2.

Beyond infection

  • In addition, it causes long-term consequences after infection, such as post-COVID syndrome (also known as long COVID), which affects millions of people.
  • The extent of the consequences of infection and reinfection on human health remains uncertain, as does the effectiveness of vaccines in limiting these effects.

The importance of vaccines

  • The final distinction from the pre-pandemic period is the arrival of RSV vaccines.
  • However, these two vaccines have not yet been officially recommended.
  • The trio of vaccines against COVID-19, influenza and RSV will certainly help to reduce the severe symptoms associated with respiratory virus infections in the coming seasons.


Nathalie Grandvaux received research funding from the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), the Fonds de recherche du Québec - Santé (FRQS), the Canada Foundation for Innovation (CFI), the Fondation du centre hospitalier de l'Université de Montréal, and the Ministère de l'économie et de l'innovation du Québec.

Jumptuit Health Announces Genesis J2T-H1: AI-Assisted Genome-Environment Geolocation Exposure Scenario Forecasting

Retrieved on: 
Monday, December 4, 2023
RSV, Allergy, Genesis, Algorithm, EGI, Humidity, Movement, Workflow, .gdn, Water, Forecasting, Biophysical environment, GDN, Altitude, Soil, Temperature, Health, Travel, Vaccine, Disease, Notification, Map, Bronchiolitis

NEW YORK, Dec. 4, 2023 /PRNewswire/ -- Jumptuit Health announces the launch of Genesis J2T-H1, AI-Assisted genome-environment geolocation exposure scenario forecasting to provide forewarning of probable impacts of environmental, disease, and toxin variables on individual health profiles. Genesis J2T-H1 provides Dynamic Individualized Susceptibility Alerts, Notifications, and Maps in geolocation-time-intervals for private and public sectors employees.

Key Points: 
  • Impact of Geosystem Co-Exposures (Environmental, Disease, and Toxin Variables) on Individual Health Profiles; Dynamic Individualized Susceptibility Alerts, Notifications, Maps in Geolocation-Time-Intervals
    NEW YORK, Dec. 4, 2023 /PRNewswire/ -- Jumptuit Health announces the launch of Genesis J2T-H1, AI-Assisted genome-environment geolocation exposure scenario forecasting to provide forewarning of probable impacts of environmental, disease, and toxin variables on individual health profiles.
  • Genesis J2T-H1 provides Dynamic Individualized Susceptibility Alerts, Notifications, and Maps in geolocation-time-intervals for private and public sectors employees.
  • Jumptuit's Genesis J2T-H1 is based on Jumptuit's Event Genesis Intelligence (EGI) that identifies the geolocation-time-intervals of future conditions, exposures, and events and generates adaptive scenario forecasting, based on continuous analyses of Real-Time-Cross-Spectrum-Data (RTCSD) captured via Jumptuit's Global Data Nets (GDNs).
  • Genesis J2T-H1 uncovers probabilities of conditions, exposures, and events prior to activities commencing and actions being taken.

FDA's greenlighting of maternal RSV vaccine represents a major step forward in protecting young babies against the virus

Retrieved on: 
Monday, August 28, 2023
Insurance, Cold medicine, Bronchiolitis, DPT vaccine, Pregnancy, Placenta, Urinary tract infection, Life, Vaccination, Hospital, Clinical trial, Parent, Infection, Diphtheria, Coagulopathy, History, Antibody, Respiratory syncytial virus, Mother, CDC, Pain, Death, RSV, Swelling, Risk, Child, Immunodeficiency, Korea Disease Control and Prevention Agency, Frustration, Preterm birth, Tetanus, Infant, Center, Birth, FDA, Pneumonia, Food, Safety, Vaccine, Birth control, Nirsevimab

RSV is the most common cause of lower respiratory infections in young children and can be especially severe for infants under 6 months of age.

Key Points: 
  • RSV is the most common cause of lower respiratory infections in young children and can be especially severe for infants under 6 months of age.
  • It is the leading cause of infant hospitalization in the U.S., according to the Centers for Disease Control and Prevention.
  • Each year, RSV is associated with half a million emergency room visits, nearly 100,000 hospitalizations and 300 deaths in young U.S. children.
  • The approval of a maternal vaccine and monoclonal antibody signals a major milestone in the medical profession’s ability to prevent RSV disease in children.

A game-changer in the fight against RSV

    • Abrysvo stimulates the mother’s immune system to produce antibodies that cross the placenta and offer protection to the newborn against RSV illness, starting at birth.
    • In the trial, the maternal RSV vaccine prevented 82% of severe lower-respiratory illnesses caused by RSV in infants in the first 3 months of life, and 69.4% through 6 months of age.
    • Abrysvo was also approved by the FDA in May 2023 to prevent RSV illness in adults 60 years and older.

Monoclonal antibodies also provide protection

    • For those who are unable to get the RSV vaccine during their pregnancy, there is also an option to provide ready-made antibodies to protect the baby.
    • These antibodies help protect against lower-respiratory tract disease, including bronchiolitis and pneumonia, caused by RSV.

Parsing the differences

    • Clinical trials showed that the vaccine was protective up to 6 months of age and the antibody up to 5 months of age.
    • While Abrysvo stimulates the production of the mother’s own antibodies that get passed on to the baby, Beyfortus is not actually a vaccine.
    • It instead provides ready-made antibodies given as an injection to protect the child.
    • The cost of Abrysvo and how it will be covered by insurance will depend on what the CDC says in October.

The bottom line

    • Both products are safe and effective, and it is important to protect young infants and children at risk from RSV.
    • Until now, effective monoclonal antibodies were only available for the most premature babies.

FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants

Retrieved on: 
Monday, August 21, 2023
Vaccine, China Biologic Products, Priority review, Bronchiolitis, Pregnancy, Pre-eclampsia, Urinary tract infection, Life, U.S. Department of Commerce Office of Security, Hospital, Gestational age, Human services, Public, Office of Inspector General, U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research, Food, Pfizer, Cosmetics, Multimedia, Respiratory syncytial virus, Animal, Trial of the century, Pain, Myalgia, Jaundice, RSV, Dietary supplement, Risk, Hypertension, Korea Disease Control and Prevention Agency, Preterm birth, Nausea, Infant, Heated tobacco product, Respiratory syncytial virus vaccine, Research, FDA, Immunization, Headache, Regulation of tobacco by the U.S. Food and Drug Administration, Pneumonia, Safety, Birth control, Pharmaceutical industry

The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals 60 years of age and older.

Key Points: 
  • The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
  • "This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease."
  • In one study, approximately 3,600 pregnant individuals received a single dose of Abrysvo and approximately 3,600 pregnant individuals received a placebo.
  • In the second study, approximately 100 pregnant individuals received Abrysvo and approximately 100 pregnant individuals received placebo.